

AMENDMENTS TO THE CLAIMS

The claims as listed below will replace all prior listings and presentations of claims in the above-identified application.

Please amend Claims 1, 4 and 48, and add new Claims 50-72 as follows:

1. **(Currently Amended)** An implant for treating an ocular disorder ~~glaucoma~~, comprising:

a body comprising material that includes a therapeutic drug, said body having an inlet portion and an outlet portion, said inlet portion configured to reside in an [[the]] anterior chamber of an eye when the outlet portion is disposed in a physiological outflow pathway of the eye, said outlet portion having an outflow opening such that said body drains ~~transports~~ fluid from the anterior chamber to the physiological outflow pathway.

2. **(Previously Presented)** The implant of Claim 1, wherein said body is coated with said therapeutic drug.

3. **(Original)** The implant of Claim 1, wherein said drug comprises heparin.

4. **(Currently Amended)** An implant for treating an ocular disorder ~~glaucoma~~, comprising:

a body having a therapeutic drug in or on said body, said body having an inlet portion and an outlet portion, said inlet portion configured to drain ~~transmit~~ fluid from an [[the]] anterior chamber of an eye to the outlet portion when the outlet portion is disposed in a physiological outflow pathway, said outlet portion having an outflow opening.

5. **(Previously presented)** The implant of Claim 4, wherein said body is coated with said therapeutic drug.

6. **(Previously Presented)** The implant of Claim 4, wherein said therapeutic drug comprises heparin.

7.-45. **(Canceled).**

46. **(Previously Presented)** The implant of Claim 1, wherein the physiological outflow pathway is Schlemm's canal.

47. **(Previously Presented)** The implant of Claim 4, wherein the physiological outflow pathway is Schlemm's canal.

48. **(Currently Amended)** A method of treating an ocular disorder glaucoma, comprising:

introducing an implant comprising a therapeutic drug into an [[the]] anterior chamber of an eye; and

advancing said implant into eye tissue adjacent the anterior chamber such that the implant drains aqueous humor from the anterior chamber into a physiological outflow pathway and the therapeutic drug reaches eye tissue ~~in which the implant is implanted~~.

49. **(Previously Presented)** The method of Claim 48, wherein the implant is coated with said therapeutic drug.

50. **(New)** The method of Claim 48, wherein advancing the implant into eye tissue involves positioning at least a portion of the implant so as to contact a choroid of the eye.

51. **(New)** The method of Claim 48, wherein advancing the implant into eye tissue involves positioning a distal end of the implant so as to drain aqueous humor toward a choroid of the eye.

52. **(New)** The implant of Claim 1, wherein the body includes a first portion and a second portion that is appended from the first portion, and wherein the first portion includes a lumen and the second portion carries the therapeutic drug.

53. **(New)** The implant of Claim 1, wherein the implant is substantially L-shaped.

54. **(New)** The implant of Claim 1, wherein the body has a sufficient length to extend from the anterior chamber into Schlemm's canal.

55. **(New)** The implant of Claim 4, wherein the body includes a first portion and a second portion that is appended from the first portion, and wherein the first portion includes a lumen and the second portion carries the therapeutic drug.

56. **(New)** The implant of Claim 4, wherein the implant comprises a protrusion configured to stabilize the implant in eye tissue.

57. **(New)** The implant of Claim 4, wherein the body has a sufficient length to extend from the anterior chamber into Schlemm's canal.

58. **(New)** A method of treating an ocular disorder, comprising:

introducing an implant comprising a therapeutic drug into an anterior chamber of an eye; and

advancing said implant into eye tissue such that the implant is in contact with at least a choroid of the eye.

59. (New) The method of Claim 58 additionally comprising draining aqueous humor from the anterior chamber into a physiologic outflow pathway through the implant.

60. (New) The method of Claim 58 additionally comprising controlling aqueous humor flow through a lumen of the implant.

61. (New) The method of Claim 58, wherein the implant includes a hollow filled with the therapeutic drug.

62. (New) The method of Claim 58, wherein the implant includes a first portion and a second portion that is appended from the first portion, the first portion including a lumen and the second portion carrying the therapeutic drug.

63. (New) The method of Claim 58, wherein the therapeutic drug comprises a compound of drugs, at least one of which is therapeutic.

64. (New) A method of treating an ocular disorder, comprising:

forming an incision in an eye;

inserting an implant through the incision into an anterior chamber of the eye, the implant comprising a therapeutic drug; and

inserting the implant into eye tissue such that the implant drains aqueous humor from the anterior chamber toward a choroid of the eye.

65. (New) The method of Claim 64 additionally comprising draining aqueous humor from the anterior chamber into a physiologic outflow pathway through the implant.

66. (New) The method of Claim 64, wherein the implant includes a first portion and a second portion that is appended from the first portion, the first portion including a lumen and the second portion carrying the therapeutic drug.

67. (New) A method of treating an ocular disorder, comprising:

placing an implant in contact with a choroid of an eye, said implant having at least one flow channel;

flowing a fluid, which comprises aqueous humor, along the flow channel of the implant; and

eluting a therapeutic agent from the implant.

68. **(New)** The method of Claim 67 additionally comprising advancing the implant through an anterior chamber of the eye toward an implantation site.

69. **(New)** The method of Claim 67 additionally comprising advancing the implant through scleral tissue of the eye toward an implantation site.

70. **(New)** A method of treating an ocular disorder, comprising:
providing an implant having at least one lumen extending between an inlet and an outlet, and at least one anchor projecting outwardly from the lumen;
using the anchor to retain the implant in eye tissue;
positioning the outlet in tissue so as to fluidically communicate directly with a physiologic outflow pathway; and
eluting a therapeutic agent from the implant.

71. **(New)** The method of Claim 70 additionally comprising advancing the implant through an anterior chamber of the eye toward an implantation site.

72. **(New)** The method of Claim 70 wherein the method further comprises advancing the implant through scleral tissue of the eye when positioning the outlet.